Effect of a MUC5AC Antibody (NPC-1C) Administered With Second-Line Gemcitabine and Nab-Paclitaxel on the Survival of Patients With Advanced Pancreatic Ductal Adenocarcinoma: A Randomized Clinical Trial

IMPORTANCE: Treatment options are limited for patients with advanced pancreatic ductal adenocarcinoma (PDAC) beyond first-line 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX), with such individuals commonly being treated with gemcitabine and nab-paclitaxel. OBJECTIVE: To determi...

Descripción completa

Detalles Bibliográficos
Autores principales: Huffman, Brandon M., Basu Mallick, Atrayee, Horick, Nora K., Wang-Gillam, Andrea, Hosein, Peter Joel, Morse, Michael A., Beg, Muhammad Shaalan, Murphy, Janet E., Mavroukakis, Sharon, Zaki, Anjum, Schlechter, Benjamin L., Sanoff, Hanna, Manz, Christopher, Wolpin, Brian M., Arlen, Philip, Lacy, Jill, Cleary, James M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2023
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9856813/
https://www.ncbi.nlm.nih.gov/pubmed/36602796
http://dx.doi.org/10.1001/jamanetworkopen.2022.49720

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9856813/
https://www.ncbi.nlm.nih.gov/pubmed/36602796
http://dx.doi.org/10.1001/jamanetworkopen.2022.49720

Ejemplares similares